Patents by Inventor Robert D'Amato

Robert D'Amato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating diseases using 3-amino thalidomide
    Publication number: 20020161023
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: June 10, 2002
    Publication date: October 31, 2002
    Inventor: Robert D'Amato
  • Method of treating diseases using 6-amino EM-12
    Publication number: 20020161024
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: June 11, 2002
    Publication date: October 31, 2002
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis with EM-138
    Patent number: 6469045
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: October 22, 2002
    Assignee: The Children's Medical Center Corporation
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis with phthaloyl glutamic acid derivatives
    Publication number: 20020119956
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as EM-12 and its derivatives have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: October 24, 2001
    Publication date: August 29, 2002
    Inventor: Robert D'Amato
  • Amino derivatives of EM-138 and methods of treating angiogenesis with same
    Patent number: 6420414
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: July 16, 2002
    Assignee: The Children's Medical Center Corporation
    Inventor: Robert D'Amato
  • PHARMACEUTICAL COMPOSITION OF 3-AMINO THALIDOMIDE
    Publication number: 20020082290
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: December 12, 2001
    Publication date: June 27, 2002
    Inventor: Robert D'Amato
  • Enantiomers of 6-amino EM-12 and method of use
    Publication number: 20020061911
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: December 20, 2001
    Publication date: May 23, 2002
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis with EM-138
    Publication number: 20020061923
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: December 19, 2001
    Publication date: May 23, 2002
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis
    Publication number: 20020049231
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: September 28, 2001
    Publication date: April 25, 2002
    Inventor: Robert D'Amato
  • Methods for the inhibition of angiogenesis with 3-amino thalidomide
    Publication number: 20010056114
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: July 5, 2001
    Publication date: December 27, 2001
    Inventor: Robert D'Amato
  • Methods for the inhibition of angiogenesis with 6-amino EM-12
    Publication number: 20010056113
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: July 5, 2001
    Publication date: December 27, 2001
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis by thalidomide
    Patent number: 6235756
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: May 22, 2001
    Assignee: The Children's Medical Center Corporation
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis
    Patent number: 6114355
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: September 5, 2000
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis
    Patent number: 6071948
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: June 6, 2000
    Assignee: The Children's Medical Center Corporation
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis
    Patent number: 5712291
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 27, 1998
    Assignee: The Children's Medical Center Corporation
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis
    Patent number: 5629327
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: December 15, 1993
    Date of Patent: May 13, 1997
    Assignee: Childrens Hospital Medical Center Corp.
    Inventor: Robert D'Amato
  • Methods and compositions for inhibition of angiogenesis
    Patent number: 5593990
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: January 14, 1997
    Assignee: The Children's Medical Center Corporation
    Inventor: Robert D'Amato